skip to Main Content

2020: a year of challenges and triumphs for FibriCheck

It’s been an exciting year for FibriCheck! And looking back at everything we achieved together with our partners in 2020, it’s remarkable how many milestones we have reached and surpassed. Read on for a brief overview of the year that…

CE approval for revolutionary (semi-)continuous monitoring technology

People suffering from potential heart rhythm disorders will soon be able to sleep a little easier. Because FibriCheck’s (semi-)continuous heart rhythm monitoring technology was recently granted CE approval by the European authorities. This is a major leap forward towards a future where users…

First step towards the Asia-Pacific region

FibriCheck gains approval from Australia’s Therapeutic Goods Administration (TGA) FibriCheck, the mobile app capable of detecting heart rhythm disorders, was granted an Australian Register of Therapeutic Goods Certificate by the Australian Government Department of Health last week. As the first…

FibriCheck guards you while you sleep

Night monitoring now closer than ever after successful beta test If you’re familiar with atrial fibrillation, you’ll know it can be a dangerous condition – the heart rhythm disorder is responsible for around 25% of all strokes1. You’ll also know…

Guaranteeing continuity of care during the lockdown and beyond

TeleCheck-AF remote screening project goes live across Europe It’s no secret the COVID-19 pandemic is placing enormous pressure on our healthcare system. Capacity in our hospitals and clinics is stretched thin. And some patients may find it hard to get…

FibriCheck selected to join the NHS Innovation Accelerator

FibriCheck has been announced as one of 11 innovations selected to join the award-winning NHS Innovation Accelerator (NIA) in 2020   FibriCheck is thrilled to be among the new innovations joining the 2020 NIA programme. FibriCheck is an innovative, hardware-free…

Back To Top
Search